SCHEMBL13600232

SCHEMBL13600232

CCOC(=O)c1ccc(-n2c(-c3ccccn3)nc3cccnc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
POLB P06746 2/20 0.56
METAP1 P53582 1/20 0.56
PABPC1 P11940 1/20 0.56
TP53 P04637 1/20 0.54
ALDH1A1 P00352 3/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
TSHR P16473 2/20 0.50
BLM P54132 1/20 0.50
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
AKT1 P31749 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13600234 0.83 MEN1 (0.66) MEN1KMT2APOLBMETAP1PABPC1
SCHEMBL13600237 0.76 SIGMAR1 (0.50) MEN1KMT2APOLBPABPC1KDM4E
SCHEMBL14686866 0.75 MAPT (0.59) MEN1KMT2APOLBTP53ALDH1A1
SCHEMBL6602550 0.75 NPC1 (0.56) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL31211646 0.75 NPC1 (0.56) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL13607180 0.75 AKT1 (0.48) MEN1KMT2APOLBPABPC1TP53
SCHEMBL15953995 0.75 PDE4B (0.66) MEN1KMT2APOLBPABPC1TSHR
SCHEMBL3008954 0.75 CSF1R (0.63) MEN1KMT2APOLBPABPC1TP53
SCHEMBL10387120 0.74 KDM4E (0.78) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL16177316 0.74 FAAH (0.51) MEN1KMT2ANPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638531-B2 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-7638531-B2 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 US disclosed
WO-2007075629-A2 PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS SCHERING CORPORATION (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists HRH4, HRH3, HRH2 MEN1 3211/4885KMT2A 1324/4885NPC1 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.